Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Capricor Therapeutics, Inc. (CAPR)

4.425   0.025 (0.57%) 03-22 12:51
Open: 4.5 Pre. Close: 4.4
High: 4.5 Low: 4.35
Volume: 20,215 Market Cap: 112(M)

Technical analysis

as of: 2023-03-22 12:15:17 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.54     One year: 6.12
Support: Support1: 3.94    Support2: 3.27
Resistance: Resistance1: 4.74    Resistance2: 5.23
Pivot: 4.61
Moving Average: MA(5): 4.44     MA(20): 4.61
MA(100): 4.29     MA(250): 4.43
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 17.5     %D(3): 15.9
RSI: RSI(14): 47.5
52-week: High: 6.57  Low: 2.8
Average Vol(K): 3-Month: 102 (K)  10-Days: 91 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CAPR ] has closed above bottom band by 22.2%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.65 - 4.67 4.67 - 4.69
Low: 4.34 - 4.37 4.37 - 4.39
Close: 4.36 - 4.4 4.4 - 4.44

Company Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Headline News

Mon, 20 Mar 2023
Capricor Therapeutics Inc to Post FY2023 Earnings of ($1.41) Per ... - MarketBeat

Sat, 18 Mar 2023
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript - Yahoo Finance

Wed, 15 Mar 2023
Capricor: Q4 Earnings Snapshot - The Washington Post

Wed, 15 Mar 2023
Capricor: Q4 Earnings Snapshot -

Wed, 08 Mar 2023
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15 - Yahoo Finance

Thu, 02 Mar 2023
Capricor Therapeutics Receives Clinical Research Forum's - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 25 (M)
% Held by Insiders 2.453e+007 (%)
% Held by Institutions 2.6 (%)
Shares Short 328 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.945e+007
EPS Est Next Qtl -0.19
EPS Est This Year -0.7
EPS Est Next Year -0.76
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 163.9
Return on Equity (ttm) 0
Qtrly Rev. Growth 2.55e+006
Gross Profit (p.s.) 0
Sales Per Share -30.33
EBITDA (p.s.) -4.71149e+006
Qtrly Earnings Growth -1.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.15
Price to Cash Flow 29.15

Stock Dividends

Dividend 0
Forward Dividend 338220
Dividend Yield 0%
Dividend Pay Date 2019-06-04
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.